Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2025 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call. At that time, if you have a question, you will need to press the star key followed by the number 1 on your touchtone phone. If anyone should require assistance during the conference, please press star then zero on your touchtone phone. As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms. Claire Trachman, Senior Vice President, Chief Investor Relations Officer at Baxter International. Ms. Trachman, you may begin.

Good morning, and welcome to our first quarter 2025 earnings conference call. Joining me today are Brent Schaefer, Baxter's Chair and Interim Chief Executive Officer, Joel Grade, Baxter's Executive Vice President and Chief Financial Officer, and Heather Knight, Baxter's Chief Operating Officer. On the call this morning, we will be discussing Baxter's first quarter 2025 results along with our financial outlook for the second quarter and full year 2025. With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook for the second quarter and full year 2025, the anticipated impact of our strategic action, the potential impact of various regulatory and operational matters in the global macroeconomic environment, including new and proposed tariffs on our results of operations, contain forward-looking statements that involve risks and uncertainties. And, of course, our actual results could differ materially from our current expectations. Please refer to today's press release in our SEC filings for more detail concerning factors that could cause actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of certain non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issue this morning, both of which are available on our website. As a reminder, continuing operations excludes Baxter's kidney care business, which is now reported as discontinued operations. Now I'd like to turn the call over to Brent.

Thanks, Claire, and good morning, everyone. Thank you for joining us. Our results for the first quarter reflect the building momentum of our strategic transformation journey and the hard work of our Baxter colleagues globally. As you saw in this morning's press release, our first quarter performance for continuing operations exceeded our previously issued guidance on both the top and bottom line. We're leveraging our verticalized operating model to create a more agile, focused product portfolio and advance innovation, improve execution, and drive profit. First quarter sales from continuing operations grew 5% on a reported and operational basis. As a reminder, continuing operations exclude the impact of our kidney care business, which was acquired by Carlyle on January 31, 2025. Sales rose in all three of Baxter's continuing segments, with performance in medical products and therapies and healthcare systems and technologies coming in ahead of expectations. Heather and Joel will share more on individual segment results later in the call. On the bottom line, adjusted earnings per share from continuing operations were $0.55. These results were fueled by top-line performance, our continued emphasis on driving operational efficiency, and a benefit from lower non-operational expenses. We're pleased with our strong Q1 performance and confident in our strategic trajectory. At the same time, we're cognizant of the volatility that is present in the global macro environment and the resulting uncertainty that has been created in the marketplace. We, like others, are keenly focused on evaluating and working to address the impact of newly enacted global tariffs and future potential tariffs, as well as a range of other interrelated factors. As you're all aware, this remains an evolving and fluid situation. Joe will walk you through our key assumptions as they relate to our financial outlook for the remainder of this year, and also how we plan to mitigate a portion of these impacts. To be clear, we remain positive about our opportunities to accelerate sales growth and expand margins. We continue to build on the strengths of our operating model and the reinvigorated profile. And as always, we benefit from our durable portfolio of medically essential products, which has served as the underlying foundation of our strength for finally I want to address a topic that I'm certain is on your mind which is the identification of Baxter's next permanent CEO well I'm not able to provide a detailed update I can confirm that the search process is active and well underway with the board being assisted by a leading search firm in these efforts as I shared previously the board is moving expeditiously but also deliberately to make sure we identify the right candidate to make the most of this opportunity to harness the potential our employees have helped, of course, keep our stakeholders updated on new developments as we are able to show. In closing, I want to recognize our global team for their dedication to our mission and outstanding contributions to Q1 performance. With that, I'll turn it over to Heather for a closer look at performance by segment.

Thanks, Brent, and welcome everyone. I'm pleased to be here with you this morning to discuss our first quarter results. I'm going to walk through our sales performance in the quarter, and then we'll hand it over to Joel to walk through performance across the rest of the P&L, along with our financial outlooks for the second quarter and full year 2025. Before I begin the sales discussion, I want to provide a reminder that results discussed on today's call will reference operational growth, which, as stated last quarter when providing guidance excludes the impact of foreign exchange, MSA revenues from Vantiv, and the planned exit of Ivy Solutions from China. As Brent referenced, and as you've seen from our release, all three Baxter segments delivered year-over-year growth for the quarter at both reported and operational rates, helping fuel company-wide top-line outperformance. First quarter 2025 global sales from continuing operations totaled 2.63 billion dollars and increased 5% on both a reported basis and operational basis. This compared favorably to our previous guidance which called for sales to increase 3% to 4% on a reported basis and approximately 4% on an operational basis. Outperformance in the quarter was led by our HST segment with particular strength in our care and connectivity solutions division along with better than expected sales in MPT. Now we'll walk through our results by reportable segments. Again commentary regarding sales growth will reflect growth on an operational basis at constant currency rates. Sales in our Medical Products and Therapies, or MPT, segment were $1.3 billion, increasing 6% in the quarter and came in ahead of expectations. Within MPT, first quarter sales from our Infusion Therapies and Technologies division totaled $994 million and increased 6%. Sales in the quarter benefited from double-digit growth for our U.S. Infusion Systems portfolio as the rollout of our Novum IQ pump platform continues. Nutrition sales in the quarter advanced mid-single digits globally, reflecting strong growth in the U.S. due to the continued progress we are experiencing in alternate sites for this business, as well as improved supply for certain products that resulted in the clearance of back orders. We also realized low single-digit growth for IV solutions. As we noted on the first quarter call, thanks to the team's stellar recovery efforts, production at our North Cove IV Solutions facility is back to pre-hurricane levels following the impact of Hurricane Helene. We are now focused on replenishing inventory and making continued progress on allocations for our customers. We expect to be on virtually all product allocations this month. IV solution sales in the quarter reflected continued conservation of fluids at hospitals across the US while the network fully recovers. Our current outlook reflects our expectation that hospitals will continue to conserve fluids in the near term but that utilization levels will improve particularly as our allocations are removed and the U.S. supply returns to normal levels. During the first quarter we did see some distributors begin to rebuild their inventory levels which helped to offset the impact from the conservation efforts. Our original expectation was that these rebuilds would likely occur more in the second quarter. Sales and advanced surgery totaled $268 million dollars and grew 4% globally. Results in the quarter reflected solid growth outside the U.S. due to increased demand for our hemostat sealants and the timing of sales to distributors. Sales in the U.S. reflected one less billing day as compared to the prior year period. In addition, the prior year period reflected the benefit of a backorder clearance for one of our hemostat products. In Healthcare Systems and Technologies, or HST, sales in the quarter were above expectations and totaled $704 million, increasing 6%. Within the HST segment, sales in the quarter for our Care and Connectivity Solutions, or CCS, division were $427 million, advancing 7% globally. Performance in the quarter was driven by 14% growth in the U.S. for CCS due to continued momentum in our patient support systems or PSS business, which once again delivered strong growth and reflected a benefit from competitive wins in both our MedSurg and ICU product lines, as well as upgrades for existing customers. Total U.S. capital orders for CCS rose 20% in the quarter, creating a healthy backlog to support future growth for this division. To date, we have not seen a slowdown in U.S. capital hospital spending, but in light of the macroeconomic uncertainty, we are closely monitoring the situation. Our focus remains on highlighting the benefits of our broad portfolio and the enhanced digital capabilities we have added to improve workflow efficiency. Performance for this division was partially offset by weaker sales outside the U.S. Importantly, we did see capital orders pick up internationally, and these are anticipated to contribute to growth over the course of the year. Frontline care sales in a quarter were $277 million and increased 5%. Performance in the quarter reflected a favorable comparison as well as continued signs of stabilization of the primary care market in the U.S. Moving to our pharmaceutical segment, sales in the quarter totaled $581 million, increasing 3%. First quarter sales within injectables and anesthesia of $335 million grew 4%. Performance in the quarter reflected mid-single-digit growth in our specialty injectables portfolio, driven by strong international growth, reflecting a government order and increased demand. This performance was partially offset by lower sales of anesthesia in the quarter. Our expectation is that the anesthesia business will begin to stabilize, and the rate of decline for this business will start to slow. Drug compounding grew 2% and reflected a difficult comparison to the prior year period. And in other sales, which represent sales not allocated to a segment and primarily includes sales of products and services provided directly through certain manufacturing facilities, were $15 million in the quarter. During the quarter, MSA revenue from Vantiv totaled $63 million. dollars. These sales are not reflected in our operational growth, but are included in our reported growth for the quarter. Before turning it over to Joel, I want to take a step back. Looking holistically, our strength across the segments reflects both the power and the trajectory of our newly defined enterprise. Our confidence and our future potential remains high, and we are committed to executing on our strategic objectives, even amid a more dynamic global macroeconomic environment. I'm confident we'll navigate this uncertainty just as we always do with the support of our 38,000 colleagues across the globe and with our mission to save and sustain lives helping define our path forward. Now I'll pass it over to Joel, who will discuss performance down the rest of the P&L, along with our updated financial outlook.

Joel? Thanks, Heather, and good morning, everyone. As my colleagues mentioned, we were pleased with our first quarter results, which came in ahead of our expectations on both the top and bottom lines. Before I begin, I want to highlight a point that both Brent and Heather referenced. We now face more dynamic, global, addressing the needs of our customers and evaluating opportunities to better optimize our supply chain network in light of new tariffs, with some activities already underway. We're accelerating our investments in innovation, focused on bringing products to the marketplace that solve the problems that our customers face and help redefine health care delivery. We're not compromised on our efforts to thoughtfully accelerate innovation in targeted areas of the business, as this is critical to support our future growth aspirations. Starting with the bottom line, first quarter adjusted earnings per share from continuing operations were 55 cents per share and came in ahead of our prior guidance of $0.47 to $0.50 per share, driven by the favorable top-line results, lower-than-expected SG&A expenses, and a benefit from TSA income and other reimbursements. In addition, our tax rate and other non-operational items gave more than offset a negative impact from foreign exchange. Before more specifically addressing the rest of the P&L results, I wanted to make some comments regarding our continuing operations reporting. As a reminder, prior to the close of the Vantip deal, corporate costs that had previously been allocated in the kidney care segment that would not convey with the kidney care business in the sale were reported in unallocated corporate costs. Post-close, these costs are now allocated to each of our segments, along with income from our Transition Services Agreements, or TSAs, as well as cost containment initiatives the company is in the process of undertaking, set the impact of these stranded costs, and loss of TSA income. In addition, during the quarter, we reclassified certain functional expenses to cost of goods sold from SG&A following the completion of the sale of our kidney care business. Functional costs were previously recorded at SG&A and support manufacturing and are now classified as indirect costs subject to inventory capitalization when sold. The cost of goods from continuing operations was 41.8%, a decrease of 160 basis points compared to the prior year. The year-over-year decline reflected the impact of NSA revenues from Vantib and higher expenses related to planning and fulfillment. First quarter adjusted SG&A from continuing operations totaled $608 million, or $23.2 as a percentage of sales, a decrease of 310 basis points from the prior year period. This year-over-year decrease reflects the benefit from the reclassification of functional costs, along with lower stock compensation expenses in the quarter, and continued discipline expense management. Adjusted R&D spending from continuing operations in the quarter totaled $138 million, and represented 5.3 as a percentage of sales an increase of 50 basis points compared to the prior year period and reflect our continued investments in advancing new products across the portfolio and bringing innovation to patients across tsa income and other reimbursements totaled 40 million dollars in the quarter this came in higher than expected and reflected increased levels of support the associated expenses are reflected in other lines of the pnl these factors resulted in an adjusted operating margin of 14.9% on a continuing operations basis, improving 260 basis points compared to the prior year period. This performance reflects continued focus on operational execution as well as the benefit of TSA income and we look at adjusted operating margin by each reportable segment. MPT's adjusted operating margin for the quarter was 19.3%, increasing 80 basis points over the prior year period and reflecting positive pricing in the quarter, partially offset by elevated costs as we continue to improve volumes at North Coast and experience higher planning and fulfillment costs. TSA income contributed to positive performance in a quarter. HST first quarter adjusted operating margins of 13.2%, a 320 basis point improvement from the prior year, driven primarily by improved to top-line performance. TSA income also contributed to performance and helped to offset increased corporate allocation expenses. Typicals adjusted operating margins were 10.8% for the quarter, decreasing 270 basis points compared to the prior year. These results reflect certain one-time expenses realized in the quarter and an increase in corporate allocations. These expenses were partially offset by TSA income. Net interest expense from continuing operations totaled $64 million in the quarter, a decrease of $14 million versus the prior year period, reflecting lower interest expense following the pay down of existing debt with proceeds from the sale of Dantip. Adjusted other non-operating income sold $17 million in the quarter compared to income of $9 million in the prior year period, primarily reflecting lower losses from foreign exchange balance sheet accounts. The continuing operations adjusted tax rate for the quarter was 17.4%, benefiting from the strategic use of select tax attributes as we optimize our global structure following the sale of kidney care. As previously mentioned, adjusted earnings from continuing operations were $0.55 per share for the quarter and increased to 53% versus the prior year. Contributions to earnings included improved commercial performance, positive pricing, the receipt of TSA income and other reimbursements, as well as the benefit of lower expenses from non-operational items, including interest and tax. Let me conclude my remarks by discussing our outlook for the full year 2025 and the second quarter of 2025, including some key assumptions underpinning the guidance. For full year 2025, Baxter expects total sales growth of 7% to 8% on a reported basis. This guidance reflects current foreign exchange rates, which are expected to minimally impact growth on the top line. This is an increase relative to our prior guidance, which had assumed that foreign exchange would negatively impact sales by approximately 200 basis points. In addition, our reported sales guidance includes a contribution of approximately $310 million of anticipated MSA revenues from Bandit, down slightly from our original expectations of $345 million. Operationally, Baxter continues to expect sales growth of 4% to 5%. As a reminder, this guidance excludes the impact of IV solutions in China. The negative impact from exiting the IV solutions business in China continues to be approximately 50 basis points to growth. Operational sales guidance for the full-year by reportable segment is as follows. For MPT, we continue to expect sales to increase approximately 5%, driven by strength in our infusion systems business, positive pricing, and other underlying business momentum. As mentioned earlier, we do expect IV solutions. This guidance excludes the impact of exiting the IV solutions market in China, which is estimated to impact sales growth by 100 basis points. We continue to expect sales in our HST segment to increase approximately 3%. While we are very pleased with the building momentum and healthy backlog we have built in HST, we will continue to closely monitor the capital environment for any changes to hospital spending expectations. We continue to expect pharmaceuticals to increase approximately 5% to 6%. Before turning to our outlook for other P&L line items, I want to provide some thoughts regarding our assumptions around tariffs. Our updated guidance now includes the estimated impact from tariffs based on the current proposals enacted, and assumes a reversion back to original proposed tariff rates following the 90-day suspension. Guidance does take into account that we are able to mitigate a portion of these impacts. In general, Baxter strives to make where we sell and buy where we make as part of our broader integrated supply chain approach. This allows us to deliver our products and solutions around the world with greater control and visibility to our operations. The majority of Baxter's products sold in the U.S. are manufactured in the U.S. and made largely from U.S.-made components. Procurement is part of our business operations, and as such, we are impacted from the U.S. and retail. We plan to take several actions to help minimize the impacts. Some of these actions will be able to be realized more near-term to help mitigate the impact in 2025, and others will require more time to be implemented, but will help offset the impact in future years. Some of these mitigation opportunities include actively communicating with and assessing our supplier base to identify risks and work to implement mitigations, which could include carrying additional inventory and identifying alternative suppliers or manufacturing locations, identifying alternative shipping routes for suppliers and finished goods to help minimize the overall impact, and finally, continuing to work closely with our trade association partners in various countries to advocate for possible exemptions. We estimate the net impact to our results from tariffs is approximately $60 to $70 million in 2020. Additionally, based on our standard rollout period, we expect to see the majority of the tariff impact in the second half of the year, that while China represents a very small percentage of our total sales, given the magnitude of the tariffs that have been enacted between the two countries, these tariffs now account for nearly half of the total impact. At this time, our tariff assumptions do not reflect any potential tariffs related to pharmaceutical products. One item I'd like to highlight is that while current foreign exchange rates are expected to benefit top-line, they do negatively impact our adjusted operating margins and adjusted earnings per share, which is driven by our current infrastructure footprint that remains post-sale of Vantiv. We have plans over time to optimize inclusive of these factors and underlying business performance. We now expect full-year adjusted operating margin from continuing operations between 16% to 16.5%. TSA income and other reimbursements are now expected to range between $140 to $150 million provided to Vantiv with the related expenses reflected in the other lines of the P&L, non-operating expenses, which include net interest expense and other income and expense, to total between $220 to $240 million. On a continuing operations basis, we anticipate a full-year tax rate of approximately 19 to approximately 515 million shares for the year, which does not contemplate any share repurchases. From all these factors, we are increasing the low end of our prior guidance range and now anticipate full-year adjusted earnings on a continuing operations basis for $2.47 to $2.55 for a diluted share. Specific to the second quarter of 2025, we expect continuing operations sales growth of approximately 4% to 5% on a reported basis and 1% to 2% on an operational basis. Ford exchange is expected to positively impact the top line by approximately 50 basis points, and MSA revenues are expected to total approximately $80 million. The China IV Solutions exit is expected to impact top-line growth by approximately 70 basis points in the second quarter. On a continuing operations basis, we expect adjusted earnings per share of $0.59 to $0.63. With that, we can now open up the call for Q&A.

Thank you. We will now begin the question and answer session. If you have a question, please press the star key followed by the number 1 on your touchtone phone. If you wish to remove yourself from the queue, press star, then one a second time. If you are using a speakerphone, please lift the handset to ask your question. So that we may be respectful of everyone's time, please limit your comments to one question with one follow-up question if necessary. We appreciate everyone's patience and would like to provide as many of you as possible the opportunity to ask a question. We will pause for a moment while the list is being compiled. I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com. Our first question comes from Joanne Uch of Citi. Your question, please.

Good morning. It's Sarianne Wench, and very nice quarter and start to the year. I have to ask the obligatory tarot question, specifically what you are pulling back on or managing to offset some of the headwinds, and then how should we think about 2026? Should we just annualize your run rate that you gave for 25? And then I'll give you my second question up front. The H2ST business, I think this was your strongest quarter since 2023. How should we think about that recovery and the sustainability? Thank you.

Thanks, Joanne. Good morning. I'll take the first part, and then I'll pass it over to Heather for the second. So from a tariff perspective, certainly we do have a number of mitigation activities, some of which are underway already, others which are continuing to be developed, that also from a timing perspective, again, there's going to be some spread on that. But I'd group it into a couple things. I mean, one from a supply chain perspective, certainly some optimization activities around negotiating with suppliers, you know, finding potential alternative supply, whether it's different suppliers, looking to do things or optimizing freight, optimizing supply. I think about, you know, routes and whether, you know, go certain things we're looking to really do to optimize those things. You know, we're certainly, you know, from a pricing standpoint, I'd say it's very targeted and not a broad strategy there necessarily. And then finally, just from continuing to seek additional exemptions, working with our government team and then the various countries we operate in and certainly in our industry groups to find different ways to potentially have exemptions for other products. So those are some of the things I'd say broadly are the things we're focused on from a mitigation perspective. And I guess what I'd say from 2026, you know, the way I would look at that, again, is I think it's probably fair, although the mitigation impacts aren't necessarily all in place now. And so those things are going to phase.

And so the impact, the mitigation activities will be phasing as we go into next year as well. so I'll for the second part no I'll pass that over to Heather yeah hi good morning Joanne and thanks for the question and thanks for acknowledging the HST performance we're really pleased with the first quarter and our teams have been working really hard with our customers so we're pleased overall with the beat it was broad-based and across all of our businesses really exceeding expectations particularly around the building momentum that we're seeing across the U.S. So we've got a healthy backlog, particularly in the PFS business, as I mentioned, strong order growth, and a lot of competitive account wins. So, you know, the commercial excellence that we talked about last year and customer programs are starting to pay off as we've managed the supply recovery that we talked about last year. While we haven't seen any slow down today in the capital environment, we are monitoring the situation, but didn't feel even based on the momentum that it was prudent to just raise guidance in HST this year, but more maintain. But overall, I would say we're happy with the momentum of the team and the business and the leadership across the organization, so thanks for the question.

Yeah, and actually, if I could just add one thing, Heather, to that, even the FLC side, you know, I think one of the things that was actually a good impact on this quarter was of balanced growth between both the CCS and frontline care. And I think we saw some stabilization, I'd say, in the primary care markets. On the FLC side, we also had less head widths in 25 and 24. We kind of talked about that heading into the year. Our backlogs are closer to normal levels in FLC. And then, obviously, we also had some favor that we're up against. But just the one I had to Heather's point there, I think, again, And it really was not only the CCS part, which we're really, you know, pleased with, but also, again, balanced really across that portfolio.

David Roman of Goldman Sachs is on the line with a question. Please state your question.

Thank you. Good morning, Heather, Joel, and Claire. I wanted just to start here on the IV side. Hospitals have been pretty successful at implementing conservation programs, and we haven't seen much of a disruption, release, it seems, from the outside in hospital operations or elective procedure volumes. So as you remove hospitals from allocation, can you maybe help us frame what you expect the impact to be to your business?

And then also, if you think hospitals will return to pre-hurricane inventory management levels, or there's something that may have more structurally changed in how they approach managing this particular supply line, then I have a follow-up on tariffs. sure hi David good morning it's Heather so I'll start so when you think about conservation it's really not across all hospitals there's a subset of hospitals that are conserving right now and we still assume in our outlook that there will be conservation as we exit the year you know in the the 10 to 12 percent range is what we're assuming when you exit the year so that's broadly for the U.S. so there are many customers that are actually using more solutions than pre-hurricane levels. So it's definitely not a one-size-fits-all, but we are assuming that conservation continues, that there's been some adjustment in practice. And we saw some of that with Hurricane Maria as well. It sort of took about a year or so for that utilization to continue. So we baked that into the forecast. I think it's important to note when you think about MPT, you know, for the half, we worked really hard to make sure that we could stabilize our customers with inventory and IV. So the timing of how we manage that in the half, we recovered really quickly and we're focused in Q1 on getting inventories back to good with our customers and with distributors. But the half, when you look at it, is really largely in line with our expectations. So that is driving how we're thinking about MPT, particularly for the first half. But I would say that customers now are starting to really think about safety stock in an area like IVs that is critical to healthcare and, you know, overall very happy with the recovery out of North Cove. And I'm really proud of our teams and the work that they did to make sure that we could get products to patients as quickly as possible. So that drove some of the overachievement in the BEAT and MPT, but largely have baked in conservation to the forecast for the rest of the year. Thanks, David.

All right, great. Thank you. Yeah, thank you for that detail. I think, Joel, on the tariff side, there was a significant amount of confusion, and I would say misinformation entered the market on your tariff exposure the past several weeks. So I understand that we don't know what the pharma tariff may or may not be, but can you give us any parameters to frame how to think about that? Because if a pharma tariff is announced between now and when you reported earnings again we're all going to try to quantify it so maybe help us understand where the exposure is how much do you uh import and finish goods from the claris plant i think it's very small but uh there's obviously an api impact maybe just walk us through the moving parts there and the level of potential exposure yeah david thanks uh i mean first of all to answer your your Claris question, that's a very small thing.

Again, that's not a material impact there. I guess I'm not sure exactly what to give you there other than how this developed. We're trying to be very proactive and thinking about sort of the scenario. At this point, though, obviously, it's still pretty up and near where that industry being generics versus some of the larger brand. Obviously, that is a size potentially. But, again, nothing really just, really nothing else to add.

Travis Steed of B of A Securities is on the line with the question. Please state your question.

I first wanted to ask a margin question, both kind of short-term and long-term. First on the gross margin, there's a little bit of a delta between your gross margin and consensus. I assume that's the reclassified certain functional expenses from COGS to SG&A. So I wanted to touch on that and kind of understand when you kind of think about TSA and MSAs over the course of this year and next year, you know, how to think about the margin impact and then longer term, you know, the path back to that kind of pre-COVID 19% operating margins for this business.

Sure. Thanks, Travis. I'll take that. A couple things. From the gross margin perspective question you had, it really comes down to, you said the reclassification is a part of this, the dilution from MFA income is also, and then just other things that I would say we're still recovering from some of the occurred in North Coast. So I think those are really some of the main, you know, some of that particular one that I talked about, we do anticipate some of that mitigating over the course. The long-term path, you know, from the TSA and MSA perspective, you know, again, our anticipation is that from a TSA perspective, you know, as I've said previously, our, you know, we anticipate those being, you know, 18 to 20 TSAs falling off, but certainly, including, you know, the TSAs being where they are this year. We talked about a 40-stranding cost perspective.

I think that's throughout the course of this year.

And MSAs as well, we did talk about the fact that it is slightly less than we had anticipated, which therefore has, again, a slightly, you know, less diluted. But I think the $310 million number we talked about, this will eventually phase out. But that's something that will be in here certainly for the next couple of years. I would say the long-term path towards margin expansion, it really comes down to a number of different items. Let's just start to continue. We've talked about the ideas of how we plan to invest in innovation, and so new product launches are certainly an element of how over time we continue to expand from a margin perspective. Certainly we see some of that this year, some GPO renegotiation coming up. From a product mix standpoint and a, again, I'll call a business mix perspective is another And then finally, things like our margin improvement programs along the way that we continue to have in our supply chain. These are areas that, again, are continuous drivers of our margin expansion in addition to obviously between now and 2027, there are the full removal, if you will, of our straining costs that are left over from the kidney and to the areas of margins and how we see that.

Dejay Kumar of Evercore ISI is online with a question. Please state your question.

Hey, guys. Thanks for taking my question and congrats on a nice execution here. Jill, maybe my first one for you on the guidance kind of question. You look at second quarter, 1% to 2% for core backshare. That's a 350 basis points decel at the midpoint from Q1 levels. I think your comps get a little bit harder, a couple of hundred basis points. So what's driving this deceleration in the second quarter in the operating margin? So prior to 16.5%, did that change because of tariffs?

Yeah, thanks. Thanks for the question. So from a revenue standpoint, Q2, it's really a couple of things that are driving that outcome. One, as we've talked about some of the conservation that is happening in some of the hospital systems from an IV fluid perspective is one of the key drivers. This is one of the things we've talked about and we've kind of previewed that we anticipated happening for a while, and we're seeing some of that, and certainly that's one of the key drivers of that impact in the second quarter. I think another part I would just say is the degree of conservative HST perspective. Obviously, as we've talked about, we're pleased with the momentum in that business. We're pleased with some of the stabilization impact on frontline care. But I guess, you know, I would just say there is an element to this that is, you know, continuing to just have some level of conservatism in that as it relates to that business in particular. But certainly those are some of the two perspectives. The other thing I would point out is that while that is the case, when you factor in a little bit of the impact you discussed in Q2, our H1, for the most part, is expected. And so the first half of the year is something that we're pretty committed to coming in. Your second question, yes, the operating margin impact that you're referencing was related to tariffs as well as some of the FX, you know, the impact that we talked about. Again, while we have some positive impact on the top line of FX, we actually do have a dilutive impact as it relates to, you know, over time.

And maybe Heather, one follow-up for you on this Nome, very strong numbers. Can you just remind us for context, like, what's been share gains over the past few quarters? Has it accelerated? And if these trends sustain, what's the downstream implication from a consumables and IV fluids standpoint? Thank you.

Yeah. Hi, Vijay. I'll tackle the first one, first question on Novum. So, you know, the backlog and pipeline on Novum is strong. So yes, we have taken market share in the low single digit range already. So there's good momentum in the Novum franchise, not just for the launch. Novum's been in the market now less than a year, but also the innovation pipeline coming behind it is pretty robust and rich. So we're excited and our customers are excited about partnering with us around Novum. A lot of the pumps in the market have been a decade plus old. So we're bringing new technology to the market with smarter, more sophisticated capabilities on interoperability with digital suites that are going to follow to supplement that launch. So a good momentum around Novum and happy with the progress. And then your second question was about consumables. Behind that was it IV Solutions?

Yes.

Yeah, so similar to what I shared with David, you know, we are seeing, we saw a steady uptick in customers rebuilding and rebalancing their inventory and consumption in the first quarter. And, you know, we're largely seeing what we expected in the half in terms of consumption and conservation. You know, some customers that maintained inventory and are, you know, taking advantage of the volumes in the market are using more than they used before the hurricane. some have concerned just as a result of you know lacking of inventory in the market but that is really starting to stabilize and as I mentioned in my opening remarks we'll have allocations off really almost fully by this month in the month of May by about mid-May so rebuilding customer confidence that they can order normally and stock their shelves normally with IV solution sets all of the things that go along with IV therapy that's been really a big part of bit working. There's just some background noise. Yeah, working with our customers. So hopefully that addresses the feasible question. But thank you, Vijay, and thanks for acknowledging the quarter.

Robby Marcus of J.P. Morgan is on the line with a question. Please state your question.

Nice quarter. Two from me. One, I guess two and a half, a quick clarifying. How much of stocking in fluids is moving uh from second quarter and then the i guess the first real question um hst had had nice performance drove a good part of the beat in the quarter maybe speak to the trends you're seeing there and how you're feeling about um the sustainability of the performance yeah robbie this is heather good morning i'll i'll start that so um in terms of the the stocking that we saw, I would say roughly about a point and a half on the total company that we saw in terms of the distributor stocking.

Again, our priority was to make sure that we could get product to customers and rebuild the network as quickly as possible so people could resume normal patient care. So, you know, having that in Q1 versus Q2 is actually a good thing. And as I said, largely in line with what we expected in the half. So about, I would think about a point and a half in terms of the total company impact. And then HST's performance, again, very pleased with the first quarter. As both Joel and I have mentioned, we've got a strong order book that we built in CCS, strong order growth. We've got competitive share gains that we've seen primarily in CCS. Additionally, we've got higher than expected nurse call installations and really positive response so far to the launch of VoltLink with Scotty. So that's CCS. So there's a lot of reasons to believe, not just in the U.S., but also building momentum OUS. And then, as Joel mentioned, FLC has largely stabilized. So we are seeing some really good benefits around our vital signs monitoring and recovering from some of the backlog in our Cuff business and strength OUS as well. So, you know, right now there's a lot of reasons to believe, but I think like many other companies that are reporting, we're being a little cautious on the capital. environment that we're seeing just because of some of the reimbursement challenges that our customers are facing, tariff concerns, and not sure how pricing is going to roll out. But, you know, internally within Baxter, we're really pleased with where HST is. You know, I think HST, we feel like is back. And based on a lot of the work that we've done around, again, commercial excellence, customer programs, partnering with our customers on the things that they need, and then furthering the integration of HST. I think we can sort of all acknowledge at the beginning of that integration, it didn't quite go as planned, but we've done a lot of work over the last 12 months to really get that business back on track and delivering the growth that we expect. So, you know, we're pretty bullish internally on HST and what that team can deliver. So, thanks for the Great.

Maybe just a quick follow-up. Joel, you put out comments for 2026. I believe it was maybe 75 to 100 basis points of operating margin expansion. You did a really impressive job offsetting the tariff impact in 2025. Does that commentary still hold for 2026 or is it under evaluation given the tariff environment.

Yeah, so thanks, Robbie. So a couple things on that. I mean, obviously, we're certainly committed to continued margin expansion. So let me just start with that. And, you know, obviously, there's a lot to play out here yet as it relates to tariffs just in general. You know, as I mentioned in our prepared remarks, we did put some pretty conservative And we're, as I also mentioned, continuing to work again our year. So, again, like continuing to really strive and execute on consistent execution, managing our expenses. And so, thanks.

Larry Beigelson of Wells Fargo is on the line with a question. Please state your question.

Good morning. Thanks for fitting me in. Congrats on a really nice quarter here. just that most might have been asked an answer. So just a couple of quick ones. Maybe Brent, just any update on the timing for, you know, CEO, permanent CEO announcement. And Joel, on just, I'll ask them both up front here. And Joel, oil prices have come down a lot. You know, we remember when oil prices were going up, it negatively impacted Baxter.

I mean, how should we think about the, you know, the reduction in oil prices potentially benefiting you thank you great I appreciate the question obviously I don't have a specific date like what I can tell you is the board is very focused it has been very diligent in their efforts to keep the process moving we're really pleased with the search firm and their efforts as well so though I can't give you an exact date we don't expect it to be an extended period I think it's making good progress. Joel?

Great. Larry, thanks again for the questions. And, you know, for those going down, the one thing I would remind that the kidney, you know, delivering a supply chain perspective at a higher level of consumption on that. So, while there is some impact, I'm not diluted pretty significantly given the fact that the kidney...

All right. Thanks so much.

Peto Csikering of Deutsche Bank is on the line with a question. Please state your question.

Hey, good morning, guys. Thanks for fitting me in here. Looking at the updated EPS guidance, definitely a lot of moving parts here. Can you bridge the previous EPS guidance to the updated EPS guidance in terms of the good guys from operational strength and FX?

So, I mean, one of the things we've talked about is the, again, continued strong operational performance. The downside of it and impact of the FX, you know, those are the main drivers of the downside of that, PSI, that those are combined at. From there, obviously, though, we continue to talk about some of the strong operational performance, as well as some underneath the line interest in taxes are obviously top to minus some of the opportunities there is the other part that's really driving that.

The T.S. wins that you saw in the U.S. this quarter, what's really driving that and how big is the backlog at this point? And then looking outside the U.S., you talked about softness in the quarter and then you talked about why it should rebound and go back to growth. I guess why do you guys see the softness and why do you think this should return back to growth? Thanks so much.

So from CCS perspective, a couple of things. I would say, again, we do have a strong backlog. I want to start with that. We've been talking about this now really since the latter part of last year that we've had a consistent, strong build. In fact, our order book broke this quarter. So I think that's really around part of what's driving that. I think, as I said in the earlier comments, there's probably an element of conservatism in this. And as you think about the, you know, I think Heather said earlier, we haven't yet seen any impact from the capital purchasing standpoint, but that's something we're certainly closely monitoring. And I would say part of the conservatism built into this is simply around that as we monitor that situation.

Yeah, I can just add to that. I mean, Peter, we've really been focused on advancing and furthering our connected care agenda, too, and the digital enhancements that we've added in the CCS portfolio, and then, you know, recovery and FLC is a big one, and then there's some new product launches also coming across that business, but in light of the dynamic environment that we're in, didn't feel like it was prudent to really raise it at this point. but the backlog is strong. The competitive wins are strong at this point. And there's been a lot of great commercial work done to further the HST business. So a lot of reasons to believe at this point.

Thanks so much.

Matt Migzik of Barclays is on the line with a question. Please state your question. Matt Migzik of Barclays, your line is open.

We can go to the next question. And that will be our final question.

Danielle and Telfi of UBS is on the line with the question. Please go ahead with your question.

Hey, good morning, everyone. Thanks so much for squeezing me in and congrats on a really good start to the year. This might be jumping the gun a little bit, but you know, it feels like now the Baxter business is stabilized back on track. And I appreciate, you know, we're awaiting a CEO announcement and all this could change. But just curious, Brent, Heather, Joel, if you guys could provide some commentary on how you're thinking about when Baxter, or maybe even just broadly the approach to organic versus inorganic investment. I know paying down debt is a top priority without a nice chunk of change to do that with the kidney care sale. So just high level thoughts there. Again, appreciating with the new CEO announcement that could change a little bit, but doubt it will change that much. So thanks so much.

Absolutely. Thanks for the question and the acknowledgement of the quarter. I'll say a couple things about that. Number one, as we've talked about, the opportunity now post-kidney is for us to really focus and target our investments around those areas that are accelerating growth. And that includes both organic and inorganic opportunities in the sense of folding, tucking deals. We have said that we anticipate our net debt to EBITDA ratio three times by the end of this year. We, despite some negative cash impact from tariffs, we still anticipate that and on target to do so. And once we, you know, so from there, then this is a time when I think, you know, our opportunity to actually start to make those kinds of investments in organic opportunities is a key part of our growth strategy. I would also say, and I know you didn't ask this, but we have not only done not having bought shares back, a program of buying stock back. So broadly speaking, certainly the capital allocation opportunity very much does change. Again, we are on target, three times at that TVDOT. Really looking forward to all those opportunities ahead.

Thank you.

Thanks very much. There are no further questions at this time. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.